GSK's Garnier: FDA raised the bar for new drugs

In an interview with the Financial Times, outgoing GSK CEO Jean-Pierre Garnier shares his thought on the new, tougher FDA approval environment. While many drug developers hope the FDA's reticence to approve new drugs in the wake of recent safety scandals will fade over time, Garnier think the regulatory environment is irrevocably changed.

"The hurdle rate has gone up. It is not going to come down. This is not a pendulum. Society wants to avoid risk. We have to tease out rare side-effects earlier," Garnier observed. Blockbusters as we know them are a dying breed. Instead, he predicted that there will be more "progressive blockbusters," drugs approved for one indication that gain other approvals over time. This approach minimizes the risk that a marketed drug could cause serious side effects that were not observed during clinical trials.

- for more on Garnier's thoughts, see this article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.